ISSN 1662-4009 (online)

ey0018.3-16 | Reviews | ESPEYB18

3.16. New therapeutic horizons for Graves' hyperthyroidism

LC Lane , TD Cheetham , P Perros , SHS Pearce

Endocr Rev. 2020;41:873–84. doi: 10.1210/endrev/bnaa022.Over the last decades, the treatment of Graves’ disease has been limited to antithyroid drugs, radioactive iodine ablation or surgery. Especially in the paediatric age group, all three therapeutic options have their advantages and side effects.New therapeutic options focus on the immune-pathophysiology ...

ey0021.3-12 | Thyroid Autoimmunity | ESPEYB21

3.12. The genetics of Graves' disease

Grixti Lydia , Lane Laura C , Pearce Simon H

Brief Summary: This article provides an in-depth review of the genetic factors contributing to Graves’ disease (GD), the most common cause of hyperthyroidism. The authors explain that GD has a strong genetic component, with genetic factors accounting for 60-80% of the risk of developing this disease. The review traces the progress of genetic studies from initial candidate gene studies to genome-wide association studies that have identified over 80 susceptibility loci. Key...

ey0018.6-14 | Longterm Effects of Hormonal Treatments in Gender Dysphoria | ESPEYB18

6.14. Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy

ES Mullins , R Geer , M Metcalf , J Piccola , A Lane , LAE Conard , TLK Mullins

Pediatrics. 2021 Mar 22:e2020023549. doi: 10.1542/peds.2020-023549. PMID: 33753543.This retrospective, single center chart review study assessed the incidence of arterial or venous thrombosis during gender affirming hormone therapy (GAHT) in 611 transgender adolescents. The prevalence of thrombosis risk factors was also investigated. No increased risk of thrombosis was found over a short ...

ey0017.6-13 | Differences/Disorders of Sex Development: Fertility | ESPEYB17

6.13. Establishing reproductive potential and advances in fertility preservation techniques for XY individuals with differences in sex development

R Islam , S Lane , SA Williams , CM Becker , GS Conway , SM Creighton

To read the full abstract: Clin Endocrinol (Oxf). 2019, Aug; 91: 237–44. doi: https://www.ncbi.nlm.nih.gov/pubmed/31004515Fertility issues in individuals with a DSD has attracted increasing attention over the past decade and are summarized in this and other reviews. The various genetic defects that cause DSD and their underlying mechanism may impair fertility in a variety of ways. I...

ey0018.1-9 | Genetics | ESPEYB18

1.9. Requirement of FAT and DCHS protocadherins during hypothalamic-pituitary development

EJ Lodge , P Xekouki , TS Silva , C Kochi , CA Longui , FR Faucz , A Santambrogio , JL Mills , N Pankratz , J Lane , D Sosnowska , T Hodgson , AL Patist , P Francis-West , F Helmbacher , C Stratakis , CL Andoniadou

JCI Insight. 2020 Oct 27;5(23):e134310. doi: 10.1172/jci.insight.134310. PMID: 33108146.Lodge et al. screened 28 patients with pituitary stalk interruption syndrome (PSIS) for mutations in the FAT/DCHS (FAT atypical cadherin/ Dachsous cadherin-related) family of protocadherins. FAT2 and DCHS2 putative damaging variants were found in 6/28 patients with ectopic ...

ey0016.1-1 | (1) | ESPEYB16

1.1. Genome-wide association analyses of chronotype in 697, 828 individuals provides insights into circadian rhythms

SE Jones , JM Lane , AR Wood , VT van Hees , J Tyrrell , RN Beaumont , AR Jeffries , HS Dashti , M Hillsdon , KS Ruth , MA Tuke , H Yaghootkar , SA Sharp , Y Jie , WD Thompson , JW Harrison , A Dawes , EM Byrne , H Tiemeier , KV Allebrandt , J Bowden , DW Ray , RM Freathy , A Murray , DR Mazzotti , PR Gehrman , DA Lawlor , TM Frayling , MK Rutter , DA Hinds , R Saxena , MN Weedon

To read the full abstract: Nat Commun 2019;10:343This paper reports many loci associated with chronotype (i.e. being a ‘morning person’ or ‘evening person’) in a genome-wide association study (GWAS) of 697, 828 participants from the UK Biobank and 23andMe cohorts. The link between chronotype and sleep timing and quality is well known. It was therefore interestin...

ey0021.14-17 | YES contributions by Dr. Simge Eren (14.17 and 14.18) | ESPEYB21

14.17. A maternal brain hormone that builds bone

Babey Muriel E. , Krause William C. , Chen Kun , Herber Candice B. , Torok Zsofia , Nikkanen Joni , Rodriguez Ruben , Zhang Xiao , Castro-Navarro Fernanda , Wang Yuting , Wheeler Erika E. , Villeda Saul , Leach J. Kent , Lane Nancy E. , Scheller Erica L. , Chan Charles K. F. , Ambrosi Thomas H. , Ingraham Holly A.

Brief Summary:This study shows that brain-derived cellular communication network factor 3 (CCN3) is a potent osteoanabolic hormone to enhance bone formation in lactating female mice. CCN3 is produced by KISS1 neurons in the brain, and operates through a unique signaling pathway that interacts with bone-forming osteoblasts leading to increased bone formation.During lactation, the increased calcium demand for milk production leads to considerable bone loss...